Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel

PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
March 27, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution

PETALUMA, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
March 09, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018

PETALUMA, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the...
March 06, 2018 19:27 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock

PETALUMA, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the closing of a public offering of 1,428,570 shares of common...
March 02, 2018 08:00 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock

PETALUMA, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the pricing of a “best efforts” public offering of up to 1,428,571...
February 07, 2018 16:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%

Product revenue up 12% compared to September 2017 quarterU.S. product revenue up 27% compared to the September 2017 quarterCash on hand equals $8.6 million at quarter end Conference Call Begins at...
January 25, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call

PETALUMA, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended...
January 09, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis

PETALUMA, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
December 05, 2017 07:05 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis

PETALUMA, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
November 16, 2017 07:45 ET | Source: Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language

PETALUMA, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right